SCHEMBL2882093

SCHEMBL2882093

Cc1cnc(-c2[nH]c3ccc(Cl)cc3c2S(=O)(=O)CC2CCC2)[nH]1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 1/20 0.36
▸ OPRD1 P41143 1/20 0.36
▸ OPRK1 P41145 1/20 0.36
▸ OPRL1 P41146 1/20 0.36
▸ LMNA P02545 5/20 0.36
▸ GAA P10253 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ HTR7 P34969 1/20 0.35
▸ HTR6 P50406 1/20 0.35
▸ KDM4E B2RXH2 4/20 0.34
▸ ALDH1A1 P00352 4/20 0.34
▸ MEN1 O00255 4/20 0.34
▸ KMT2A Q03164 4/20 0.34
▸ PTGS2 P35354 4/20 0.34
▸ MAPT P10636 3/20 0.34
▸ EIF2AK2 P19525 1/20 0.33
▸ POLB P06746 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2879925 0.82 COMT (0.38) OPRM1OPRD1OPRK1OPRL1LMNA
SCHEMBL13233715 0.80 GAA (0.42) LMNAGAAHPGDCYP1A2HTR1A
SCHEMBL2882193 0.79 CYP1A2 (0.36) LMNAGAAHPGDCYP1A2HTR1A
SCHEMBL2882280 0.77 CYP1A2 (0.38) LMNAGAAHPGDCYP1A2HTR1A
SCHEMBL2876719 0.75 ALOX15 (0.40) OPRM1OPRD1OPRK1OPRL1LMNA
SCHEMBL2882120 0.74 SIRT1 (0.38) OPRM1OPRD1OPRK1OPRL1LMNA
SCHEMBL4313647 0.73 ALDH1A1 (0.53) LMNAGAAHPGDCYP1A2KDM4E
SCHEMBL4319804 0.72 MAP2 (0.48) MAPTMAPK1ALOX15SMN1; SMN2
SCHEMBL4310041 0.70 ALDH1A1 (0.52) LMNAGAAHPGDCYP1A2KDM4E
SCHEMBL4319380 0.70 MAP2 (0.47) PTGS2MAPTMAPK1ALOX15SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168097-A1 Non-Nucleoside Reverse Transcriptase Inhibitors MERCK SHARP & DOHME CORP. 2010-07-01 — — US claimed
EP-1898928-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2008-03-19 — — EP claimed
WO-2007002458-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2007-01-04 — — WO claimed
US-20100168097-A1 Non-Nucleoside Reverse Transcriptase Inhibitors MERCK SHARP & DOHME CORP. 2010-07-01 — — US disclosed
US-20100168097-A1 Non-Nucleoside Reverse Transcriptase Inhibitors MERCK SHARP & DOHME CORP. 2010-07-01 — — US disclosed
US-20100168097-A1 Non-Nucleoside Reverse Transcriptase Inhibitors MERCK SHARP & DOHME CORP. 2010-07-01 — — US disclosed
EP-1898928-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2008-03-19 — — EP disclosed
WO-2007002458-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2007-01-04 — — WO disclosed
WO-2007002458-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2007-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168097-A1 Non-Nucleoside Reverse Transcriptase Inhibitors RNGTT, POLR1E, RTF1 OPRM1 2583/4885OPRD1 2063/4885OPRK1 2626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback